Skip to main content

Human Akt1 (E17K Mutation) Alexa Fluor™ Plus 680-conjugated Antibody

R&D Systems, part of Bio-Techne | Catalog # FAB6815AFP680

Catalog #
Availability
Size / Price
Qty
Loading...
FAB6815AFP680-100UG

Key Product Details

Species Reactivity

Human

Applications

Western Blot, Immunocytochemistry

Label

Alexa Fluor Plus 680 (Excitation = 687 nm, Emission = 704 nm)

Antibody Source

Monoclonal Mouse IgG1 Clone # 710022

Product Specifications

Immunogen

Synthetic peptide containing human Akt1 Ala5-Lys30 with Glu17Lys mutation

Specificity

Detects human AKT1 with Glu17Lys mutation in Western blots. In Western blots, no cross‑reactivity with 293‑EBNA human EBV-expressing embryonic kidney cell line transfectant expressing wild type AKT1 is detected.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications

Application
Recommended Usage

Immunocytochemistry

Optimal dilution of this antibody should be experimentally determined.

Western Blot

Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Formulation

Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

Background: Akt1

Akt, also known as protein kinase B (PKB), is a central kinase in such diverse cellular processes as glucose uptake, cell cycle progression, and apoptosis. Three highly homologous members define the Akt family: Akt1 (PKB alpha), Akt2 (PKB beta), and Akt3 (PKB gamma). All three Akts contain an amino-terminal pleckstrin homology domain, a central kinase domain, and a carboxyl-terminal regulatory domain. Akt1 is the most widely expressed family member and is frequently activated in a number of carcinomas, including breast, prostate, lung, pancreatic, liver, ovarian, and colorectal cancer. Akt1 is activated in a multistep process that involves the sequential phosphorylation of Thr450 by JNK kinases, Thr308 by PDK1, and Ser473 by PDK2 or mTORC2. Activated Akt1 phosphorylates a wide variety of cytosolic, nuclear, and mitochondrial substrates. Substitution of glutamic acid with lysine at amino acid 17 (E17K) occurs in multiple malignancies and results in constitutive Akt1 activation and cell transformation. Within aa 5‑30, human Akt1 shares 100% aa sequence identity with mouse and rat Akt1.

References

  1. Carpten, J.D. et al. (2007) Nature 448:439.
  2. Bleeker, F.E. et al. (2008) Oncogene 27:5648.
  3. Brugge, J. et al. Cancer Cell 12:104.

Long Name

v-Akt Murine Thymoma Viral Oncogene Homolog 1

Alternate Names

PKB alpha, PRKBA, RAC-alpha

Entrez Gene IDs

207 (Human); 11651 (Mouse); 25233 (Rat)

Gene Symbol

AKT1

UniProt

Additional Akt1 Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices


This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

For research use only

Loading...
Loading...
Loading...
Loading...